Lupin Ltd.

Drugmakers Lupin Ltd and Cipla Ltd will make way for the two banks, according to a statement from Asia Index Pvt Ltd.

The government today cleared 14 foreign investment proposals, including that of Lupin Ltd and Alkem Laboratories Ltd.

Drug maker Cadila Healthcare Ltd said on Tuesday it launched in India the first biosimilar version of the anti-inflammatory medicine adalimumab, the world's top-selling drug, at a fifth of its US price.

Technical indicators point towards some correction in Indian equity markets next week as it seems to have become overbought after a 3.5 per cent rally in the Sensex in April, according to traders.

German drugmaker Bayer has filed a suit in the United States against Indian generic drug maker Lupin, to prevent it from selling a version of Bayer's birth-control pill Natazia there.

Lupin Ltd has informed BSE that the Allotment Committee of Directors at its meeting held on September 07, 2011 has allotted 62243 fully paid up equity shares of Rs. 2/- each. These shares have been allotted upon exercising of options granted to the employees under Stock option plans of the Company. In view of the above, the issued and paid up capit...

With reference to the news item appearing in a leading financial daily titled "Takeda in Talks to Acquire Cipla or Lupin Pharma Biz", Lupin Ltd has clarified to BSE that the Company is not in discussions with Takeda for the purposes of selling its domestic formulations business as mentioned in the aforesaid article. As such, the new report ...

Lupin Ltd has announced the following results for the quarter ended June 30, 2011: The Unaudited results for the Quarter ended June 30, 2011. The Company has posted a net profit of Rs. 727.50 million for the quarter ended June 30, 2011 as compared to Rs. 1574.20 million for the quarter ended June 30, 2010. Total Income has increased from Rs. 10096....

Lupin Ltd has informed BSE that the Allotment Committee of Directors at its meeting held on July 29, 2011 has allotted 137032 fully paid up equity shares of Rs. 2/- each. These shares have been allotted upon exercising of options granted to the employees under Stock option plans of the Company. In view of the above, the issued and paid up capital o...

Lupin Ltd has informed BSE regarding a Press Release dated July 29, 2011 titled "Eli Lilly India and Lupin announce strategic collaboration to help fight the battle against diabetes"

Lupin Ltd has informed BSE that the Company has granted 1845750 options to its employees under "Lupin Employees Stock Option Plan 2011" at the exercise price of Rs. 455.65 on August 02, 2011. One equity share of Rs. 2/- each is covered by each option. The options issued are exercisable at the 'market price' as defined in SEBI guidel...

Lupin Ltd has submitted to BSE a copy of minutes of the 29th Annual General Meeting.

Lupin Ltd has informed BSE that the Company has granted 19,000 options to its employee of its subsidiary Company, under "Lupin Subsidiary Companies Employees Stock Option Plan 2011", at the exercise price of Rs. 458.30 on July 13, 2011.  One equity share of Rs. 2/- each is covered by each option. The options issued are exercisable at t...

Lupin Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 27, 2011 inter alia, to consider the unaudited financial results for the quarter ended June 30, 2011 (Q1).

Drugmakers Lupin Ltd and Cipla Ltd will make way for the two banks, according to a statement from Asia Index Pvt Ltd.

The government today cleared 14 foreign investment proposals, including that of Lupin Ltd and Alkem Laboratories Ltd.

Drug maker Cadila Healthcare Ltd said on Tuesday it launched in India the first biosimilar version of the anti-inflammatory medicine adalimumab, the world's top-selling drug, at a fifth of its US price.

Technical indicators point towards some correction in Indian equity markets next week as it seems to have become overbought after a 3.5 per cent rally in the Sensex in April, according to traders.

German drugmaker Bayer has filed a suit in the United States against Indian generic drug maker Lupin, to prevent it from selling a version of Bayer's birth-control pill Natazia there.

Lupin Ltd has informed BSE that the Allotment Committee of Directors at its meeting held on September 07, 2011 has allotted 62243 fully paid up equity shares of Rs. 2/- each. These shares have been allotted upon exercising of options granted to the employees under Stock option plans of the Company. In view of the above, the issued and paid up capit...

With reference to the news item appearing in a leading financial daily titled "Takeda in Talks to Acquire Cipla or Lupin Pharma Biz", Lupin Ltd has clarified to BSE that the Company is not in discussions with Takeda for the purposes of selling its domestic formulations business as mentioned in the aforesaid article. As such, the new report ...

Lupin Ltd has announced the following results for the quarter ended June 30, 2011: The Unaudited results for the Quarter ended June 30, 2011. The Company has posted a net profit of Rs. 727.50 million for the quarter ended June 30, 2011 as compared to Rs. 1574.20 million for the quarter ended June 30, 2010. Total Income has increased from Rs. 10096....

Lupin Ltd has informed BSE that the Allotment Committee of Directors at its meeting held on July 29, 2011 has allotted 137032 fully paid up equity shares of Rs. 2/- each. These shares have been allotted upon exercising of options granted to the employees under Stock option plans of the Company. In view of the above, the issued and paid up capital o...

Lupin Ltd has informed BSE regarding a Press Release dated July 29, 2011 titled "Eli Lilly India and Lupin announce strategic collaboration to help fight the battle against diabetes"

Lupin Ltd has informed BSE that the Company has granted 1845750 options to its employees under "Lupin Employees Stock Option Plan 2011" at the exercise price of Rs. 455.65 on August 02, 2011. One equity share of Rs. 2/- each is covered by each option. The options issued are exercisable at the 'market price' as defined in SEBI guidel...

Lupin Ltd has submitted to BSE a copy of minutes of the 29th Annual General Meeting.

Lupin Ltd has informed BSE that the Company has granted 19,000 options to its employee of its subsidiary Company, under "Lupin Subsidiary Companies Employees Stock Option Plan 2011", at the exercise price of Rs. 458.30 on July 13, 2011.  One equity share of Rs. 2/- each is covered by each option. The options issued are exercisable at t...

Lupin Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 27, 2011 inter alia, to consider the unaudited financial results for the quarter ended June 30, 2011 (Q1).